Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Other Non-Current Liabilities (2017 - 2025)

Historic Other Non-Current Liabilities for Arcus Biosciences (RCUS) over the last 9 years, with Q3 2025 value amounting to $152.0 million.

  • Arcus Biosciences' Other Non-Current Liabilities rose 1176.47% to $152.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $152.0 million, marking a year-over-year increase of 1176.47%. This contributed to the annual value of $157.0 million for FY2024, which is 1056.34% up from last year.
  • As of Q3 2025, Arcus Biosciences' Other Non-Current Liabilities stood at $152.0 million, which was up 1176.47% from $159.0 million recorded in Q2 2025.
  • Arcus Biosciences' Other Non-Current Liabilities' 5-year high stood at $166.0 million during Q1 2025, with a 5-year trough of $10.2 million in Q1 2021.
  • Moreover, its 5-year median value for Other Non-Current Liabilities was $140.0 million (2022), whereas its average is $103.2 million.
  • Per our database at Business Quant, Arcus Biosciences' Other Non-Current Liabilities skyrocketed by 2236777.16% in 2021 and then tumbled by 620.69% in 2024.
  • Over the past 5 years, Arcus Biosciences' Other Non-Current Liabilities (Quarter) stood at $122.0 million in 2021, then increased by 14.75% to $140.0 million in 2022, then grew by 1.43% to $142.0 million in 2023, then grew by 10.56% to $157.0 million in 2024, then decreased by 3.18% to $152.0 million in 2025.
  • Its last three reported values are $152.0 million in Q3 2025, $159.0 million for Q2 2025, and $166.0 million during Q1 2025.